Ask AI
ProCE Banner Activity

Optimizing Bispecific Antibody Safety and Care Coordination in RRMM: The Oncology Pharmacist Perspective

Clinical Thought

Pharmacist experience and drug knowledge are essential for safe management and care coordination for patients with relapsed/refractory multiple myeloma (RRMM) who receive bispecific antibodies during their treatment. In this commentary, experts will describe key considerations for individualizing bispecific antibody therapy, important patient counseling points, their current prophylaxis approach, and how their institutions have operationalized outpatient step-up dosing for patients with RRMM. Special attention is given to the major toxicities—CRS and ICANS—and how pharmacists help reduce the risk of these adverse events during step-up dosing in the inpatient and outpatient settings.

Released: July 30, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with multiple myeloma.  

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize key toxicities such as cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, cytopenias, infections, and agent-specific effects, using current guideline-based tools and protocols

  • Interpret clinical trial data and real-world evidence to differentiate bispecific antibodies by targets, dosing strategies, safety profiles, and administration nuances, facilitating optimal agent selection and sequencing in relapsed/refractory multiple myeloma

  • Develop competence in multidisciplinary care coordination, including managing inpatient ramp-up and outpatient maintenance workflows, emergency department collaboration for AE emergencies, and adherence to mandated REMS requirements

  • Build skills to effectively counsel patients and caregivers on therapy expectations, AE recognition and reporting, infection prevention, adherence, and navigate equitable access challenges, especially for underserved populations

Program Director Disclosure

Primary Author

Syeda Saba Kareem, PharmD, BCOP: consultant/advisor/speaker: Janssen, Pfizer, Regeneron, Sanofi.

Sara A. Scott, PharmD, BCOP: consultant/advisor/speaker: GlaxoSmithKline, Pfizer, Sanofi.